表达Wnt3a的癌症干细胞损害CD8+TRM功能,导致黑色素瘤免疫疗法抵抗
Julián A Gajón1,2, Angel Juarez-Flores3, Fatima Mendoza-Roldan2
1Posgrado en Ciencias Bioquímicas, Universidad Nacional Autónoma de México, Ciudad de México, México.
Oncoimmunology
|December 4, 2025
概括
Wnt通路的激活驱动癌症干细胞,通过损害CD8+T细胞导致黑色素瘤抗PD-1免疫疗法的抵抗. 抑制Wnt信号恢复T细胞功能并逆转抵抗.
科学领域:
- 在瘤学瘤学.
- 免疫学 免疫学 免疫学
- 癌症干细胞 癌症干细胞
背景情况:
- 免疫检查点阻塞 (ICB) 在晚期黑色素瘤中表现有前途,但许多患者没有反应.
- 抗PD-1治疗的抗药性机制,一个关键的ICB,尚未完全理解.
研究的目的:
- 研究黑色素瘤中抗PD-1耐药性的机制.
- 确定潜在的治疗点,以克服ICB耐药性.
主要方法:
- 开发出抗PD-1 耐药的小鼠黑色素瘤细胞系 (R1,R2).
- 评估瘤开始,侵入性和转移.
- 分析了癌症干细胞 (CSC) 种群和T细胞透/功能.
- 研究了Wnt/β-catenin的信号抑制in vitro和in vivo.
- 在公开的黑色素瘤队列上进行了转录基因分析.
主要成果:
- 抗性黑色素瘤细胞显示瘤发病率,侵入性和转移率增加.
- 富含Wnt3a过度表达的CSC样群体与减少CD8+组织居民记忆 (TRM) T细胞透和功能相关.
- 在体外,Wnt/β-catenin抑制增强了CD8+ T细胞的增殖和功能.
- 在体内,Wnt/β-catenin抑制逆转了抗PD-1耐药性,减少了CSC,并恢复了CD8+TRMs.
- 人类黑色素瘤队列中的Wnt通路丰富与预后不佳和ICB耐药性相关.
结论:
- Wnt/β-catenin信号传递促进癌症干和抑制抗瘤CD8+T细胞反应,有助于黑色素瘤的抗PD-1抵抗.
- 准Wnt通路是一种潜在的策略,可以提高ICB在非响应性黑色素瘤患者的疗效.
相关概念视频
Cancer Stem Cells and Tumor Maintenance
5.8K
Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
5.8K
Tumor Immunotherapy
1.7K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
1.7K
The Tumor Microenvironment
7.6K
Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
7.6K
Treatment Resistant Cancers
3.7K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.7K


